Unknown

Dataset Information

0

Analyses of functions of an anti-PD-L1/TGF?R2 bispecific fusion protein (M7824).


ABSTRACT: M7824 (MSB0011359C) is a novel first-in-class bifunctional fusion protein consisting of a fully human IgG1 anti-PD-L1 monoclonal antibody (with structural similarities to avelumab) linked to the extracellular domain of two TGF? receptor 2 (TGF?R2) molecules serving as a TGF? Trap. Avelumab has demonstrated clinical activity in a range of human cancers and has been approved by the Food and Drug Administration for the therapy of Merkel cell and bladder carcinomas. Preclinical studies have shown this anti-PD-L1 is capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC). In the studies reported here, it is shown that M7824 is also capable of mediating ADCC of a wide range of human carcinoma cells in vitro, employing natural killer (NK) cells as effectors, albeit not as potent as anti-PD-L1 employing some tumor cells as targets. The addition of the IL-15 superagonist fusion protein complex ALT-803 enhanced the ADCC capacity of both anti-PD-L1 and M7824, and to levels that both agents now demonstrated similar levels of ADCC of tumor cells. TGF? is a known immunosuppressive entity. Studies reported here show TGF?1 induced reduction of several NK activation markers as well as reduction of endogenous NK lytic activity and NK-mediated ADCC of tumor cells. These phenomena could be reduced or mitigated, however, by M7824, but not by anti-PD-L1. M7824, but not anti-PD-L1, was also shown to reduce the immunosuppressive activity of regulatory T cells on human CD4+ T-cell proliferation. These studies thus demonstrate the dual functionalities of M7824 and provide the rationale for its further clinical development.

SUBMITTER: Jochems C 

PROVIDER: S-EPMC5650414 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).

Jochems Caroline C   Tritsch Sarah R SR   Pellom Samuel Troy ST   Su Zhen Z   Soon-Shiong Patrick P   Wong Hing C HC   Gulley James L JL   Schlom Jeffrey J  

Oncotarget 20170908 43


M7824 (MSB0011359C) is a novel first-in-class bifunctional fusion protein consisting of a fully human IgG1 anti-PD-L1 monoclonal antibody (with structural similarities to avelumab) linked to the extracellular domain of two TGFβ receptor 2 (TGFβR2) molecules serving as a TGFβ Trap. Avelumab has demonstrated clinical activity in a range of human cancers and has been approved by the Food and Drug Administration for the therapy of Merkel cell and bladder carcinomas. Preclinical studies have shown th  ...[more]

Similar Datasets

| S-EPMC5927523 | biostudies-literature
| S-EPMC5665067 | biostudies-literature
2018-01-18 | GSE107801 | GEO
| S-EPMC7985967 | biostudies-literature
| S-EPMC5835162 | biostudies-literature
2023-03-11 | PXD037102 | Pride
| S-EPMC6216129 | biostudies-literature
| S-EPMC8156979 | biostudies-literature
| S-EPMC8753312 | biostudies-literature